Sofosbuvir/Velpatasvir · more major-labeled pairs than Bictegravir
SPL labels Sofosbuvir/Velpatasvir + Bictegravir as minor; Sofosbuvir/Velpatasvir 20 / Bictegravir 16 in that band.
Mechanism on file: There are no known significant interactions between these two medications based on clinical research.
FDA SPL severity: Minor
Sofosbuvir/Velpatasvir + Bictegravir · SPL mechanism field
There are no known significant interactions between these two medications based on clinical research.
Minor band excerpt · Sofosbuvir/Velpatasvir with Bictegravir
7.6 Drugs without Clinically Significant Interactions with BIKTARVY Based on drug interaction studies conducted with BIKTARVY or the components of BIKTARVY, no clinically significant drug interactions have been observed when BIKTARVY is combined with the following drugs: ethinyl estradiol, ledipasvir/sofosbuvir, midazolam, norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir.
Sofosbuvir/Velpatasvir · 3 major-labeled pairs (vs Bictegravir's 2)
- Atorvastatin minor
- Dabigatran minor
- Darunavir minor
- Digoxin minor
Bictegravir · 16 minor + 19 total pairs
- Acyclovir minor
- Carbamazepine minor
- Cidofovir minor
- Estradiol minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.